Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing’s disease
25 April 2012 | By Novartis
Novartis announced that the European Commission has approved Signifor®...
List view / Grid view
News
Amgen to acquire Mustafa Nevzat
25 April 2012 | By Amgen
Amgen and Mustafa Nevzat Pharmaceuticals have announced an agreement under which Amgen will acquire 95.6 percent of shares in MN...
B&W Tek is awarded patent for mounting fiber spectroscopic probes on to microscope
24 April 2012 | By B&W Tek Inc
B&W Tek, Inc., has announced its 18th patent since the company’s establishment in 1997...
Gerresheimer presents innovative solutions at Interphex N.Y.
24 April 2012 | By Gerresheimer AG
Gerresheimer will be displaying its comprehensive range of tubular glass based primary packaging solutions at Interphex...
Novo Nordisk and Oxford University team up to develop novel treatments for rheumatoid arthritis
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash)
23 April 2012 | By AstraZeneca
Deal includes lead product lesinurad in Phase III development for gout...
Takeda and AMAG receive a positive CHMP opinion in Europe for Rienso® (ferumoxytol)
23 April 2012 | By Takeda Pharmaceutical Company Limited
For the treatment of iron deficiency anaemia in adult chronic kidney disease patients...
FORXIGA (dapagliflozin) receives positive CHMP opinion in the EU for the treatment of type 2 diabetes
23 April 2012 | By AstraZeneca
In combination with other glucose-lowering medicinal products including insulin...
GlaxoSmithKline reaches agreement to divest non-core OTC brands for £164 million
23 April 2012 | By GlaxoSmithKline Plc
Announcement follows divestment of brands in USA, Canada & Europe...
Two phase 3 studies on ultra-long-acting insulin degludec published in The Lancet
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
A tribute to George Rathmann, Amgen’s founding CEO (1927-2012)
23 April 2012 | By Amgen
Amgen has announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away...
Genzyme demonstrates depth of MS pipeline at AAN with results from Miltiple Sclerosis Phase III trials
20 April 2012 | By Sanofi
Full CARE-MS II results for Alemtuzumab to be unveiled...
Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients with the life-threatening blood cancer myelofibrosis
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...
FORXIGA® (dapagliflozin) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
20 April 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of the EMA has recommended approval of FORXIGA® (dapagliflozin) tablets...
Abbott receives U.S. FDA clearance to use iFS Advanced Femtosecond Laser technology for arcuate incisions in cataract surgery
20 April 2012 | By Abbott
Abbott has received U.S. FDA clearance to use its iFS Advanced Femtosecond Laser...
